Jade Biosciences, Inc. $JBIO Stock Position Increased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lifted its holdings in shares of Jade Biosciences, Inc. (NASDAQ:JBIO) by 64.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,205,972 shares of the company’s stock after buying an additional 472,204 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Jade Biosciences were worth $16,944,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC acquired a new stake in Jade Biosciences in the 1st quarter valued at $43,557,000. Stempoint Capital LP acquired a new position in Jade Biosciences during the first quarter worth $2,164,000. Renaissance Technologies LLC raised its position in Jade Biosciences by 94.0% during the first quarter. Renaissance Technologies LLC now owns 135,039 shares of the company’s stock worth $1,897,000 after acquiring an additional 65,438 shares during the period. Bank of New York Mellon Corp acquired a new position in Jade Biosciences during the second quarter worth $1,896,000. Finally, Corient Private Wealth LP acquired a new position in Jade Biosciences during the second quarter worth $1,367,000.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Wall Street Zen downgraded shares of Jade Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Jefferies Financial Group reissued a “buy” rating and set a $48.00 target price on shares of Jade Biosciences in a research note on Tuesday, August 11th. BTIG Research restated a “buy” rating and set a $77.00 price target on shares of Jade Biosciences in a research report on Tuesday, October 27th. Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Jade Biosciences in a research report on Thursday, October 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Jade Biosciences in a research note on Friday, September 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.

Jade Biosciences Stock Down 4.1%

Shares of NASDAQ:JBIO opened at $15.87 on Friday. Jade Biosciences, Inc. has a 1 year low of $9.51 and a 1 year high of $28.00. The business’s 50 day moving average price is $15.40 and its 200-day moving average price is $18.14.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts anticipate that Jade Biosciences, Inc. will post -2.89 EPS for the current year.

Jade Biosciences Profile

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.